Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Case Comprehensive Cancer Center
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
University of California, San Francisco
Assistance Publique - Hôpitaux de Paris
M.D. Anderson Cancer Center
Mayo Clinic
UNICANCER
Mayo Clinic
Mayo Clinic
Fudan University
Institut de cancérologie Strasbourg Europe
University Hospital, Montpellier
University Hospital, Rouen
Centre Leon Berard
The Netherlands Cancer Institute